ES2090598T3 - Procedimiento de ensayo de proteinas de union de hormonas inmunofuncional mediado por ligando. - Google Patents

Procedimiento de ensayo de proteinas de union de hormonas inmunofuncional mediado por ligando.

Info

Publication number
ES2090598T3
ES2090598T3 ES92901281T ES92901281T ES2090598T3 ES 2090598 T3 ES2090598 T3 ES 2090598T3 ES 92901281 T ES92901281 T ES 92901281T ES 92901281 T ES92901281 T ES 92901281T ES 2090598 T3 ES2090598 T3 ES 2090598T3
Authority
ES
Spain
Prior art keywords
hormone
binding protein
bound
growth
lifa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901281T
Other languages
English (en)
Inventor
Lena Mariana Susann Carlsson
Ross Graham Clark
Wai Lee Tan Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2090598T3 publication Critical patent/ES2090598T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

UN METODO DE ENSAYO INMUNOFUNCIONAL POR MEDIO DE LIGANTE (LIFA) PARA DETECTAR LA PRESENCIA Y LA CONCENTRACION DE PROTEINAS LIGANTES DE HORMONA DE POLIPEPTIDO QUE COMPRENDE CAPTURAR LA PROTEINA LIGANTE CON PRIMER ANTICUERPO UNIDO A UNA FASE SOLIDA, SATURAR LA PROTEINA LIGANTE DE HORMONA UNIDA CON LA HORMONA DE POLIPEPTIDO LIGANTE, Y DETECTAR LA HORMONA DE POLIPEPTIDO LIGANTE UNIDA CON UN ANTICUERPO SEGUNDO MARCADO Y DETECTABLE ESPECIFICO PARA LA HORMONA DE POLIPEPTIDO LIGANTE. EN AUSENCIA DE HORMONA DE POLIPEPTIDO SATURANTE AÑADIDO, EL LIFA MIDE LA CANTIDAD DE PROTEINA LIGANTE DE HORMONA UNIDA A LA HORMONA DE POLIPEPTIDO LIGANTE ENDOGENO. UN ENSAYO DE PROTEINA LIGANTE DE HORMONA DEL CRECIMIENTO MUESTRA EL METODO DEL PRESENTE INVENTO. LOS RESULTADOS DEL ENSAYO LIFA INDICAN QUE LA PROTEINA LIGANTE INCREMENTADA AUMENTA BASICAMENTE LA ACTIVIDAD DE LA HORMONA DEL CRECIMIENTO. SE MUESTRAN METODOS DE USO Y FORMULACIONES DE PROTEINA LIGANTE DE HORMONA DEL CRECIMIENTO, HORMONA DEL CRECIMIENTO, PROTEINA LIGANTE DE FACTOR DEL CRECIMIENTO DEL TIPO INSULINA Y DE FACTOR DE CRECIMIENTO I DEL TIPO INSULINA.
ES92901281T 1990-11-19 1991-11-19 Procedimiento de ensayo de proteinas de union de hormonas inmunofuncional mediado por ligando. Expired - Lifetime ES2090598T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/615,538 US5210017A (en) 1990-11-19 1990-11-19 Ligand-mediated immunofunctional hormone binding protein assay method

Publications (1)

Publication Number Publication Date
ES2090598T3 true ES2090598T3 (es) 1996-10-16

Family

ID=24465822

Family Applications (3)

Application Number Title Priority Date Filing Date
ES99123825T Expired - Lifetime ES2324322T3 (es) 1990-11-19 1991-11-19 Uso de igf-1 solo o combinado con la hormona de crecimiento para estimular el crecimiento.
ES92901281T Expired - Lifetime ES2090598T3 (es) 1990-11-19 1991-11-19 Procedimiento de ensayo de proteinas de union de hormonas inmunofuncional mediado por ligando.
ES95110334T Expired - Lifetime ES2171478T3 (es) 1990-11-19 1991-11-19 Composicion farmaceutica que comprende la hormona de crecimiento y la proteina unidora de la hormona de crecimiento.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99123825T Expired - Lifetime ES2324322T3 (es) 1990-11-19 1991-11-19 Uso de igf-1 solo o combinado con la hormona de crecimiento para estimular el crecimiento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95110334T Expired - Lifetime ES2171478T3 (es) 1990-11-19 1991-11-19 Composicion farmaceutica que comprende la hormona de crecimiento y la proteina unidora de la hormona de crecimiento.

Country Status (12)

Country Link
US (1) US5210017A (es)
EP (3) EP0681842B1 (es)
JP (2) JP2977280B2 (es)
AT (3) ATE138739T1 (es)
AU (1) AU657109B2 (es)
CA (1) CA2093927C (es)
DE (3) DE69133614D1 (es)
DK (3) DK0558647T3 (es)
ES (3) ES2324322T3 (es)
GR (1) GR3020505T3 (es)
HK (1) HK1007351A1 (es)
WO (1) WO1992008985A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866350A (en) * 1985-03-19 1999-02-02 Helen Hwai-An Lee Method for the immunological determination of a biological material in a sample
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6326154B1 (en) * 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5464757A (en) * 1991-01-15 1995-11-07 The Salk Institute For Biological Studies DNA encoding CRF binding protein
MD1699F2 (ro) * 1992-07-31 2001-07-31 Genentech, Inc. Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
US6087188A (en) * 1992-11-13 2000-07-11 Alk A/S Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US6403764B1 (en) * 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
SE0300959D0 (sv) * 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor
US7713574B2 (en) 2004-07-13 2010-05-11 Dexcom, Inc. Transcutaneous analyte sensor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE263537C (es) *
NL7501215A (nl) * 1975-02-01 1976-08-03 Akzo Nv Methode voor het aantonen en bepalen van een antigeen of antilichaam.
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4476228A (en) * 1982-11-08 1984-10-09 Abbott Laboratories Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques
US4622293A (en) * 1983-07-05 1986-11-11 Miles Laboratories, Inc. Iodothyronine immunoassays employing HMS as TBP blocking agent
US4594327A (en) * 1983-11-02 1986-06-10 Syntex (U.S.A.) Inc. Assay method for whole blood samples
EP0491675A1 (en) * 1984-01-30 1992-06-24 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JPS63273496A (ja) * 1987-05-01 1988-11-10 Sumitomo Pharmaceut Co Ltd モノクロ−ナル抗体、ハイブリド−マおよびヒト成長ホルモン測定方法
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
DD263537A1 (de) * 1987-09-01 1989-01-04 Akad Wissenschaften Ddr Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes wachstumshormon
US4956302A (en) * 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
GB2233091B (en) * 1988-01-28 1992-05-27 Du Pont Immunoassays using monoclonal antibodies directed against natural binding proteins
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
EP0418230B1 (en) * 1988-04-12 1995-12-27 Amgen Boulder Inc. Method for potentiating and inhibiting insulin-like growth factor activity
WO1990000569A1 (en) * 1988-07-15 1990-01-25 Central Sydney Area Health Service Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
US5330971A (en) * 1989-06-09 1994-07-19 Gropep Pty. Ltd. Growth hormone fusion proteins, methods of production, and methods of treatment
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy

Also Published As

Publication number Publication date
EP0995445A3 (en) 2004-01-07
JP2977280B2 (ja) 1999-11-15
ES2171478T3 (es) 2002-09-16
CA2093927A1 (en) 1992-05-20
DE69132931T2 (de) 2002-11-28
DE69119911T2 (de) 1996-11-21
EP0558647A1 (en) 1993-09-08
WO1992008985A3 (en) 1992-10-29
US5210017A (en) 1993-05-11
WO1992008985A2 (en) 1992-05-29
ATE213165T1 (de) 2002-02-15
DE69119911D1 (de) 1996-07-04
EP0995445A2 (en) 2000-04-26
JP3159966B2 (ja) 2001-04-23
ATE425764T1 (de) 2009-04-15
ES2324322T3 (es) 2009-08-04
EP0681842A2 (en) 1995-11-15
DK0995445T3 (da) 2009-07-06
AU9106791A (en) 1992-06-11
EP0681842A3 (en) 1998-06-10
DE69132931D1 (de) 2002-03-21
DK0681842T3 (da) 2002-06-03
DK0558647T3 (da) 1996-08-19
CA2093927C (en) 2000-07-18
ATE138739T1 (de) 1996-06-15
EP0558647B1 (en) 1996-05-29
JPH11346765A (ja) 1999-12-21
HK1007351A1 (en) 1999-04-09
JPH06502724A (ja) 1994-03-24
EP0995445B1 (en) 2009-03-18
AU657109B2 (en) 1995-03-02
GR3020505T3 (en) 1996-10-31
DE69133614D1 (de) 2009-04-30
EP0681842B1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
ES2090598T3 (es) Procedimiento de ensayo de proteinas de union de hormonas inmunofuncional mediado por ligando.
EE05460B1 (et) Lahustuv retseptor BR43x2 ja selle kasutamise meetodid
ATE98776T1 (de) Monoklonale antikoerper fuer hba1c.
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
CA2291983A1 (en) Ligand-mediated immunofunctional hormone binding protein assay method
KR860002573A (ko) 펩타이드 항체의 제조방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 558647

Country of ref document: ES

FG2A Definitive protection

Ref document number: 558647

Country of ref document: ES